Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 851 to 900 of 2008 results for news

  1. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.

  2. Ovarian cancer (QS18)

    This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.

  3. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

  4. Blood transfusion (QS138)

    This quality standard covers blood transfusion and reducing the requirements for blood transfusion in adults, young people and children aged 1 year and over. It describes high-quality care in priority areas for improvement. It does not cover use of tranexamic acid for surgery during pregnancy or labour or blood transfusion during pregnancy or labour.

  5. Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)

    Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making

  6. Screening assessment tools:- Develop reliable and valid screening assessment tools for attachment and sensitivity that can be made available and used in routine health, social care and education settings.

    and after an intervention.A cohort study is needed to validate any tool (new or existing) that can identify children and young people...

  7. Risdiplam for treating spinal muscular atrophy (TA755)

    Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in people of all ages.

  8. Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.

  9. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

  10. Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection (HTG634)

    Evidence-based recommendations on aortic remodelling hybrid stent insertion for acute type A aortic dissection. This involves inserting a stent with material sewed on one end into part of the aorta.

  11. Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)

    NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .

  12. Hepatitis B and C testing: people at risk of infection (PH43)

    This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.

  13. Urinary tract infection in under 16s: diagnosis and management (NG224)

    This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management. It does not cover babies, children and young people with urinary catheters in situ, neurogenic bladders, significant pre-existing urinary tract disorders (uropathies), underlying renal disease or immunosuppression, or recurrent UTI in sexually active girls and young women under 16. It also does not cover babies, children and young people in intensive care units.

  14. Generalised anxiety disorder and panic disorder in adults: management (CG113)

    This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.

  15. Harmful sexual behaviour among children and young people (NG55)

    This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.

  16. Attention deficit hyperactivity disorder: diagnosis and management (NG87)

    This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.

  17. Major trauma: assessment and initial management (NG39)

    This guideline covers the rapid identification and early management of major trauma in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by improving the quality of their immediate care. It does not cover care for people with burns.

  18. Learning disabilities and behaviour that challenges: service design and delivery (NG93)

    This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.

  19. Optilume for treating recurrent bulbar urethral strictures (HTG649)

    Evidence-based recommendations on Optilume for treating recurrent bulbar urethral strictures.

  20. Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)

    This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.

  21. Kidney cancer: diagnosis and management (NG256)

    This guideline covers diagnosing and managing renal cell carcinoma in people aged 18 and over. It aims to improve care by helping healthcare professionals offer people the right treatments and support, taking into account the person’s individual preferences.

  22. Erectile dysfunction: Alprostadil cream (ESNM50)

    Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

  23. ImmunoCAP ISAC 112 for multiplex allergen testing (HTG413)

    Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.

  24. Endoscopic axillary lymph node retrieval for breast cancer (HTG93)

    Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer. This involves using narrow instruments to remove the lymph nodes through small, rather than large, openings to reduce the risk of infection and other problems.

  25. Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)

    Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.

  26. Vandetanib for treating medullary thyroid cancer (TA550)

    Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

  27. Digital health technologies: What is the clinical and cost effectiveness of digital health technologies in people with epilepsy?

    the rationale section on new technologies. Full details of the evidence and the committee's discussion are in evidence review 5:...

  28. 3C Patch for treating diabetic foot ulcers (HTG615)

    Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.

  29. Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy (MIB316)

    NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy .

  30. Tofacitinib for moderately to severely active ulcerative colitis (TA547)

    Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.

  31. The social care guidance manual (PMG10)

    This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used

  32. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.

  33. Laparoscopic retroperitoneal lymph node dissection for testicular cancer (HTG102)

    Evidence-based recommendations on laparoscopic retroperitoneal lymph node dissection for testicular cancer. This involves using smaller openings in the skin (keyhole surgery) to remove the lymph nodes.

  34. Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (HTG222)

    Evidence-based recommendations on percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. This involves using a special device to block the mouth of the left atrial appendage and stop the blood clot from getting into the bloodstream.

  35. Smartinhaler for asthma (MIB90)

    NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .

  36. KODEX-EPD for cardiac imaging during ablation of arrhythmias (MIB260)

    NICE has developed a medtech innovation briefing (MIB) on KODEX-EPD for cardiac imaging during ablation of arrhythmias .

  37. MRI-guided focused ultrasound subthalamotomy for treating Parkinson's (HTG734)

    Evidence-based recommendations on MRI-guided focused ultrasound subthalamotomy for treating Parkinson’s. This involves using ultrasound to destroy tissue in an area of the brain linked to Parkinson’s symptoms.

  38. Nerve graft for corneal denervation (HTG629)

    Evidence-based recommendations on nerve graft for corneal denervation. This involves attaching a healthy nerve to the damaged cornea to improve healing.

  39. Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis (HTG704)

    Evidence-based recommendations on percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. This involves using a wire mesh tube called a stent to widen the narrowed carotid artery.

  40. Radiofrequency cold ablation for respiratory papillomatosis (HTG295)

    Evidence-based recommendations on radiofrequency cold ablation for respiratory papillomatosis. This involves using an electrical current to dissolve or shrink the papillomas (non-cancerous growths).

  41. Insertion of pleuro–amniotic shunt for fetal pleural effusion (HTG123)

    Evidence-based recommendations on inserting a pleuro-amniotic shunt to drain pleural effusions in a fetus during pregnancy. This involves inserting a drainage tube through the fetal chest wall into the pleural space, allowing fluid to drain into the amniotic cavity.

  42. Irreversible electroporation for treating liver metastases (HTG304)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

  43. Thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism (HTG266)

    Evidence-based recommendations on thoracoscopic exclusion of the left atrial appendage in atrial fibrillation (with or without other cardiac surgery) for the prevention of thromboembolism. This involves inserting a camera and instruments through small cuts in the chest and closing the left atrial appendage.

  44. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

  45. Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)

    Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.

  46. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.

  47. Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

    Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.

  48. Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)

    Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.

  49. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

  50. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.